Will the 2027 ACA Open Enrollment period see a 15% increase in participation compared to 2026?

This market resolves to Yes if a recognized health agency officially reports a significant outbreak of waterborne or other infectious diseases in Colombo, Sri Lanka due to the recent flooding by November 30, 2026. A 'significant outbreak' is defined as more than 100 confirmed cases from diseases such as leptospirosis, hepatitis A, typhoid, dengue or similar within this timeframe.

This market resolves to Yes if a new lung health breakthrough, funded by the American Lung Association, is published in a peer-reviewed journal by December 31, 2026. The breakthrough must be a significant advancement or discovery in lung health fields such as lung cancer, asthma, COPD, or other respiratory threats.

This market resolves to Yes if publicly verifiable reports or official announcements confirm that the da Vinci 5 robotic surgical system has been deployed in at least 500 additional hospitals worldwide by December 31, 2027. The count will include hospitals that adopt the system for the first time or upgrade from older models to the da Vinci 5. Deployment must be substantiated by Intuitive Surgical (the manufacturer), validated press releases, or other credible sources by the resolution date.

Will any U.S. hospital perform a fully remote robotic surgery with the da Vinci 5 system by January 31, 2027?

This market resolves to Yes if any U.S. hospital performs a fully remote (surgeon operating from a physically separate location) robotic surgery using the da Vinci 5 system by January 31, 2027. Verification will depend on public announcements, press releases, or trusted reporting from reputable medical or news organizations.

This market resolves to Yes if the FDA officially approves any AI-based tool for translating clinical trial consent forms by March 31, 2027. Approval must be publicly announced by the FDA or the tool's developers, and explicitly described as intended for use in translating clinical trial consent forms.

This market resolves to Yes if peer-reviewed study results published by March 2027 show that the dual-drug strategy significantly improves clinical outcomes (such as progression-free survival or overall response rate) for patients with triple-negative breast cancer compared to current standard treatments.